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Clinics and pathology 
Disease 
ANLL/MDS: only treatment related leukaemias cases 
so far (in other 11q23 translocations, most cases occur 
in de novo acute leukaemia). 
Phenotype / cell stem origin 
M4, M2 ANLL; CMML and RAEBT, although MDS is 
otherwise rarely seen in 11q23 translocations; the 
fusion gene is found in all the mature monocytes, in 
some of the granulocytes and erythroblasts, not in the 
lymphocytes. 
Epidemiology 
13 available cases; most cases are children cases: 
median age is 10-14 yrs, range is 2-74 yrs; sex ratio is 
balanced. 
Clinics 
Secondary to antitopoisomerase II drugs (etoposide or 
teniposide, but also doxorubicin); this secondary 
malignancy occurs within 6-60 mths (median 20 mths); 
the primary malignancy was a t(8;21)(q22;q22)/M2-





Are found in 8 of 11 cases; variable, except the 
unexpectected recurrence of 1p36.1 involvement. 






DNA / RNA 
21 exons, spanning over 100 kb; 13-15 kb mRNA. 
Protein 
431 kDa; contains two DNA binding motifs (a AT 
hook, and Zinc fingers), a DNA methyl transferase 
motif, a bromodomain; transcriptional regulatory 




Nuclear localisation; transcriptional 
adaptor/coactivator: binds CREB; has histone 
acetyltransferase activity. 




5' MLL - 3' CBP 
Fusion protein 
Description 
N-term AT hook and DNA methyltransferase from 
MLL fused to most of CBP starting with the 
bromodomain of CBP -or even more in N-term with the 
CREB binding domain- and also comprising the 
cystein/histidine rich and the glutamine rich domains of 
CBP in C-term around 1400 amino acids from MLL; 
the reciprocal CBP-MLL may or may not be expressed. 
Oncogenesis 
May promote histone acetylation of genomic regions 
targeted by the MLL AT-hooks; may loose CBP cell 
cycle inhibition capability. 
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